These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
360 related articles for article (PubMed ID: 22837675)
1. O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions. Villalva C; Cortes U; Wager M; Tourani JM; Rivet P; Marquant C; Martin S; Turhan AG; Karayan-Tapon L Int J Mol Sci; 2012; 13(6):6983-6994. PubMed ID: 22837675 [TBL] [Abstract][Full Text] [Related]
2. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. Melguizo C; Prados J; González B; Ortiz R; Concha A; Alvarez PJ; Madeddu R; Perazzoli G; Oliver JA; López R; Rodríguez-Serrano F; Aránega A J Transl Med; 2012 Dec; 10():250. PubMed ID: 23245659 [TBL] [Abstract][Full Text] [Related]
3. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells. Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841 [TBL] [Abstract][Full Text] [Related]
4. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay? Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H J Neurosurg; 2019 Mar; 130(3):780-788. PubMed ID: 29726772 [TBL] [Abstract][Full Text] [Related]
5. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status. Wu Q; Berglund AE; Macaulay RJ; Etame AB Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894860 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762 [TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas. Ochsenbein AF; Schubert AD; Vassella E; Mariani L J Neurooncol; 2011 Jun; 103(2):343-51. PubMed ID: 20857319 [TBL] [Abstract][Full Text] [Related]
8. MGMT promoter methylation in plasma of glioma patients receiving temozolomide. Fiano V; Trevisan M; Trevisan E; Senetta R; Castiglione A; Sacerdote C; Gillio-Tos A; De Marco L; Grasso C; Magistrello M; Tondat F; Rudà R; Cassoni P; Soffietti R; Merletti F J Neurooncol; 2014 Apr; 117(2):347-57. PubMed ID: 24519517 [TBL] [Abstract][Full Text] [Related]
9. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. Minniti G; Salvati M; Arcella A; Buttarelli F; D'Elia A; Lanzetta G; Esposito V; Scarpino S; Maurizi Enrici R; Giangaspero F J Neurooncol; 2011 Apr; 102(2):311-6. PubMed ID: 20686820 [TBL] [Abstract][Full Text] [Related]
10. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. van Nifterik KA; van den Berg J; van der Meide WF; Ameziane N; Wedekind LE; Steenbergen RD; Leenstra S; Lafleur MV; Slotman BJ; Stalpers LJ; Sminia P Br J Cancer; 2010 Jun; 103(1):29-35. PubMed ID: 20517307 [TBL] [Abstract][Full Text] [Related]
11. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952 [TBL] [Abstract][Full Text] [Related]
12. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
13. The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status. Chen WJ; Zhang X; Han H; Lv JN; Kang EM; Zhang YL; Liu WP; He XS; Wang J; Wang GH; Yu YB; Zhang W Cell Death Dis; 2020 Aug; 11(8):668. PubMed ID: 32820151 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049 [TBL] [Abstract][Full Text] [Related]
17. dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma. Zapanta Rinonos S; Li T; Pianka ST; Prins TJ; Eldred BSC; Kevan BM; Liau LM; Nghiemphu PL; Cloughesy TF; Lai A J Neurooncol; 2024 Jan; 166(1):129-142. PubMed ID: 38224404 [TBL] [Abstract][Full Text] [Related]
18. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829 [TBL] [Abstract][Full Text] [Related]
19. Effect of IFN-beta on human glioma cell lines with temozolomide resistance. Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561 [TBL] [Abstract][Full Text] [Related]
20. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. Jung TY; Jung S; Moon KS; Kim IY; Kang SS; Kim YH; Park CS; Lee KH Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]